The following markers were downregulated during tumor development: CD45+ (92.03% to 71.38% in culture vs in tumors, respectively; p<0.0001), CD45+GFP+ (82.04% to 25.12%; p<0.0001), CD19+ (99.3% to 98.9%; p = 0.012), CD20+ (91.0% to 63.1%; p<0.0001), CD22+ (48.24% to 9.21%; p<0.0001), and CD138+ (25.52% to 12.0%; p = 0.011). The gene discussed is CD19; the disease is neoplasm.